{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:39:30Z","timestamp":1770421170806,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cll.2023.08.010","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T06:19:53Z","timestamp":1716963593000},"page":"181-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Molecular Pathology of Urothelial Carcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Hikmat","family":"Al-Ahmadie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Netto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAP.0000000000000252","article-title":"Updates on the genomics of bladder cancer and novel molecular taxonomy","volume":"27","author":"Al-Ahmadie","year":"2020","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.cll.2023.08.010_bib3","series-title":"World Health Organization classification of tumours","article-title":"WHO Classification of tumours of the urinary system and male genital organs","author":"Moch","year":"2016"},{"issue":"6512","key":"10.1016\/j.cll.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.aba8347","article-title":"Extensive heterogeneity in somatic mutation and selection in the human bladder","volume":"370","author":"Lawson","year":"2020","journal-title":"Science"},{"issue":"6512","key":"10.1016\/j.cll.2023.08.010_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1126\/science.aba7300","article-title":"Macroscopic somatic clonal expansion in morphologically normal human urothelium","volume":"370","author":"Li","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.cll.2023.08.010_bib6","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.molonc.2016.08.003","article-title":"Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma","volume":"10","author":"Thomsen","year":"2016","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.cll.2023.08.010_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.5250","article-title":"Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy","volume":"248","author":"Heide","year":"2019","journal-title":"J\u00a0Pathol"},{"issue":"7457","key":"10.1016\/j.cll.2023.08.010_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cll.2023.08.010_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.cll.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cll.2023.08.010_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2017.11","article-title":"The evolving genomic landscape of urothelial carcinoma","volume":"14","author":"Glaser","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"8","key":"10.1016\/j.cll.2023.08.010_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-018-0026-y","article-title":"Treatment resistance in urothelial carcinoma: an evolutionary perspective","volume":"15","author":"Vlachostergios","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ng.3557","article-title":"Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors","volume":"48","author":"Kim","year":"2016","journal-title":"Nat Genet"},{"issue":"14","key":"10.1016\/j.cll.2023.08.010_bib14","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.cll.2023.08.010_bib15","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.cll.2023.08.010_bib16","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1002\/cncr.30219","article-title":"Genomic characterization of response to chemoradiation in urothelial bladder cancer","volume":"122","author":"Desai","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.cll.2023.08.010_bib17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.cll.2023.08.010_bib18","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1200\/JCO.2018.78.2425","article-title":"DNA repair deficiency and immunotherapy response","volume":"36","author":"Mouw","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.cll.2023.08.010_bib19","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","article-title":"Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer","volume":"36","author":"Iyer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.cll.2023.08.010_bib20","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7691","key":"10.1016\/j.cll.2023.08.010_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.cll.2023.08.010_bib22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.cll.2023.08.010_bib23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2023.08.010_bib24","series-title":"FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma","year":"2019"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41379-020-0453-z","article-title":"PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates","volume":"33","author":"Taylor","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PAS.0000000000000305","article-title":"Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation","volume":"39","author":"Zhong","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.anndiagpath.2015.06.007","article-title":"Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder","volume":"19","author":"Vail","year":"2015","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"10.1016\/j.cll.2023.08.010_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/his.13318","article-title":"Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma","volume":"72","author":"Brown","year":"2018","journal-title":"Histopathology"},{"issue":"24","key":"10.1016\/j.cll.2023.08.010_bib29","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.cll.2023.08.010_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/path.5261","article-title":"Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder","volume":"248","author":"Isharwal","year":"2019","journal-title":"J\u00a0Pathol"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/his.13441","article-title":"Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential","volume":"72","author":"Wang","year":"2018","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.cll.2023.08.010_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.euf.2017.07.004","article-title":"Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma","volume":"5","author":"Isharwal","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.cll.2023.08.010_bib33","doi-asserted-by":"crossref","first-page":"e32143","DOI":"10.7554\/eLife.32143","article-title":"Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy","volume":"7","author":"Springer","year":"2018","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.cll.2023.08.010_bib34","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41379-019-0276-y","article-title":"Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma","volume":"32","author":"Eich","year":"2019","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib35","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.cll.2023.08.010_bib36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.cll.2023.08.010_bib37","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"10.1016\/j.cll.2023.08.010_bib38","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A\u00a0molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cll.2023.08.010_bib39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sjodahl","year":"2013","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.cll.2023.08.010_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A\u00a0consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/BLC-150037","article-title":"Bladder cancer molecular taxonomy: summary from a consensus meeting","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.cll.2023.08.010_bib43","series-title":"Precision molecular pathology of bladder cancer","first-page":"43","article-title":"Genomic assessment of muscle-invasive bladder cancer: insights from the cancer genome atlas (TCGA) project","author":"Kim","year":"2018"},{"issue":"10031","key":"10.1016\/j.cll.2023.08.010_bib44","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cll.2023.08.010_bib45","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","article-title":"Small cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis","volume":"24","author":"Chang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib46","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A\u00a0validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.cll.2023.08.010_bib47","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib49","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.eururo.2018.06.047","article-title":"Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications","volume":"74","author":"Hovelson","year":"2018","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.cll.2023.08.010_bib50","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41379-018-0096-5","article-title":"Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases","volume":"31","author":"Sjodahl","year":"2018","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.cll.2023.08.010_bib51","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/ijc.32737","article-title":"Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma","volume":"146","author":"Sjodahl","year":"2020","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.cll.2023.08.010_bib52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2023.08.010_bib53","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications","volume":"22","author":"Amin","year":"2009","journal-title":"Mod Pathol"},{"issue":"7492","key":"10.1016\/j.cll.2023.08.010_bib54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib56","first-page":"1692","article-title":"The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer?","volume":"190","author":"Linder","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.cll.2023.08.010_bib57","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.cll.2023.08.010_bib58","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00428-020-02787-8","article-title":"Comparative genomic profiling of glandular bladder tumours","volume":"477","author":"Maurer","year":"2020","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.cll.2023.08.010_bib59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.cll.2023.08.010_bib60","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ijc.25700","article-title":"The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma","volume":"129","author":"Keck","year":"2011","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.cll.2023.08.010_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/PAS.0b013e318186c45e","article-title":"Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases","volume":"33","author":"Nigwekar","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib62","first-page":"1656","article-title":"Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib63","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.urology.2013.12.035","article-title":"Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes","volume":"83","author":"Kaimakliotis","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.cll.2023.08.010_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.10.033","article-title":"Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations","volume":"85","author":"Palsgrove","year":"2019","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamaoncol.2019.3985","article-title":"Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care","volume":"6","author":"Penson","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib66","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/modpathol.2013.201","article-title":"Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome","volume":"27","author":"Schneider","year":"2014","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib67","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-015-1729-4","article-title":"Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer","volume":"466","author":"Tschui","year":"2015","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.cll.2023.08.010_bib68","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/modpathol.2011.69","article-title":"HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in\u00a0situ hybridization","volume":"24","author":"Ching","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cll.2023.08.010_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","article-title":"Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma","volume":"77","author":"Isharwal","year":"2018","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.cll.2023.08.010_bib70","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.cll.2023.08.010_bib71","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A\u00a0high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cll.2023.08.010_bib72","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","article-title":"Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer","volume":"70","author":"Guo","year":"2016","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.cll.2023.08.010_bib73","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1038\/s41388-018-0192-5","article-title":"Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics","volume":"37","author":"Shen","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib74","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-neural plasticity drives progression to small cell bladder cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib75","first-page":"1497","article-title":"Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases","volume":"159","author":"Lopez-Beltran","year":"1998","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib76","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5858\/arpa.2015-0085-OA","article-title":"Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition","volume":"140","author":"Sanfrancesco","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.cll.2023.08.010_bib77","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/path.2129","article-title":"Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation","volume":"211","author":"Sung","year":"2007","journal-title":"J\u00a0Pathol"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib78","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","article-title":"Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer","volume":"27","author":"Guo","year":"2019","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.cll.2023.08.010_bib79","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.urolonc.2019.09.025","article-title":"Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer","volume":"37","author":"Genitsch","year":"2019","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.cll.2023.08.010_bib80","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.MP.0000094091.04541.FC","article-title":"Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases","volume":"16","author":"Lin","year":"2003","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.cll.2023.08.010_bib81","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.humpath.2009.07.015","article-title":"Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases","volume":"41","author":"Wasco","year":"2010","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib82","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/his.13280","article-title":"Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases","volume":"71","author":"Comperat","year":"2017","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.cll.2023.08.010_bib83","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/PAS.0b013e318222a653","article-title":"Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma","volume":"35","author":"Cox","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.cll.2023.08.010_bib84","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.5858\/2007-131-1725-NVOUC","article-title":"Nested variant of urothelial carcinoma","volume":"131","author":"Dhall","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"10.1016\/j.cll.2023.08.010_bib85","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/00000478-200309000-00008","article-title":"Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma","volume":"27","author":"Volmar","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.cll.2023.08.010_bib86","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/his.13958","article-title":"Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma","volume":"75","author":"Weyerer","year":"2019","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.cll.2023.08.010_bib87","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/cancers12030763","article-title":"Pure Large Nested Variant of Urothelial Carcinoma (LNUC) is the prototype of an FGFR3 mutated aggressive urothelial carcinoma with luminal-papillary phenotype","volume":"12","author":"Weyerer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.cll.2023.08.010_bib88","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/ajcp\/aqaa160","article-title":"Nested variant of urothelial carcinoma is a luminal bladder tumor with distinct coexpression of the basal marker cytokeratin 5\/6","volume":"155","author":"Johnson","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.cll.2023.08.010_bib89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"10.1016\/j.cll.2023.08.010_bib90","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271223000872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271223000872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T11:50:26Z","timestamp":1717242626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271223000872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0272271223000872"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2023.08.010","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Pathology of Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}